作为项目负责人，目前主持科研项目或入选人才计划共9项：

1.   国家自然科学基金青年项目(No. 82003759)  

2.   中国科协第九届青年人才托举工程(2023QNRC001)

3.   上海市青年科技英才扬帆计划(20YF1437500) 

4.   上海市“晨光计划”(21CGA21)  

5.   中央高校基本科研业务费专项基金(22120240303)

6.   同济大学附属第十人民医院攀登人才计划(2021SYPDRC026)  

7.   中国青年医学创新研究科研课题(P24072298864)

8.   同济大学附属第十人民医院国自然院内培育项目青年A类(04.03.19.135)  

9.   中关村精准医学基金(ZGC-YXKY-26)

10.  上海青年药学人才能力提升项目A类(SPAQNRC2025A02)

目前作为第一作者（含共一第一）或通讯作者（含共同通讯）发表SCI论文10篇：

1. Targeting GPX4 alleviates ferroptosis and retards abdominal aortic aneurysm formation. Biochem Pharmacol, 2025. (IF=5.6, Q1) 

2. Activation of α7 nicotinic acetylcholine receptors inhibits hepatic necroptosis and ameliorates acute liver injury in mice. Anesthesiology, 2024. (IF=9.1, Q1) 

3. Colchicine protects against the development of experimental abdominal aortic aneurysm. Clin Sci (Lond), 2023. (IF=7.7, Q1)   

4. Activating α7nAChR ameliorates abdominal aortic aneurysm through inhibiting pyroptosis mediated by NLRP3 inflammasome. Acta Pharmacol Sin, 2022. (IF=8.4, Q1) 

5. Exerkine fifibronectin type-III domain-containing protein 5/irisin-enriched extracellular vesicles delay vascular ageing by increasing SIRT6 stability. Eur Heart J, 2022. (IF=35.6, Q1)  

6. Effects of low-level mercury exposure on brain-derived neurotrophic factor in preschool children. Ecotoxicol Environ Saf, 2021. (IF=6.1, Q1)

7.  Inflammasome-independent NALP3 contributes to high-salt induced endothelial dysfunction. Front Pharmacol, 2018. (IF=4.8, Q1)

8. Cholinergic anti-inflammatory pathway inhibits neointimal hyperplasia by suppressing inflammation and oxidative stress. Redox Biol, 2018. (IF=11.9, Q1)

9. Targeting α7 nicotinic acetylcholine receptor to combat inflammation in cardio-cerebral-vascular diseases. Curr Drug Targets, 2017. (IF=2.5, Q2)

10. Vagus nerve attenuates hepatocyte apoptosis upon ischemia-reperfusion via α7 nicotinic acetylcholine receptor on kupffer cells in mice. Anesthesiology, 2016. (IF=9.1, Q1)